Solasia Pharma K.K. Logo

Solasia Pharma K.K.

Develops and commercializes in-licensed oncology drugs for Asian markets.

4597 | T

Overview

Corporate Details

ISIN(s):
JP3436500007
LEI:
Country:
Japan
Address:
港区芝公園二丁目11番1号

Description

Solasia Pharma K.K. is a specialty pharmaceutical company focused on oncology. The company's business model involves in-licensing promising drug candidates to develop and commercialize them for patients in Asian markets. Its portfolio is centered on addressing unmet medical needs in both cancer treatment and supportive care, aiming to improve patients' quality of life. Key commercialized products include Sancuso® for chemotherapy-induced nausea and vomiting (CINV), DARVIAS® for peripheral T-cell lymphoma (PTCL), and episil® oral liquid, a medical device for pain associated with oral mucositis. The development pipeline includes candidates for treating chemotherapy-induced peripheral neuropathy (CIPN) and colorectal cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-03-22 07:16
内部統制報告書-第16期(2023/01/01-2023/12/31)
Japanese ZIP 22.7 KB
2024-03-22 07:15
確認書
Japanese ZIP 8.1 KB
2024-03-22 07:13
有価証券報告書-第16期(2023/01/01-2023/12/31)
Japanese ZIP 1.7 MB
2023-11-13 08:15
確認書
Japanese ZIP 8.1 KB
2023-11-13 08:14
四半期報告書-第16期第3四半期(2023/07/01-2023/09/30)
Japanese ZIP 187.3 KB
2023-08-10 08:41
確認書
Japanese ZIP 8.1 KB
2023-08-10 08:40
四半期報告書-第16期第2四半期(2023/04/01-2023/06/30)
Japanese ZIP 196.2 KB
2023-05-15 08:43
確認書
Japanese ZIP 8.1 KB
2023-05-15 08:42
四半期報告書-第16期第1四半期(2023/01/01-2023/03/31)
Japanese ZIP 173.4 KB
2023-03-23 07:43
内部統制報告書-第15期(2022/01/01-2022/12/31)
Japanese ZIP 22.7 KB
2023-03-23 07:43
確認書
Japanese ZIP 8.1 KB
2023-03-23 07:42
有価証券報告書-第15期(2022/01/01-2022/12/31)
Japanese ZIP 1.7 MB
2022-11-14 07:40
確認書
Japanese ZIP 8.2 KB
2022-11-14 07:40
四半期報告書-第15期第3四半期(令和4年7月1日-令和4年9月30日)
Japanese ZIP 406.8 KB
2022-08-18 09:35
確認書
Japanese ZIP 8.2 KB

Automate Your Workflow. Get a real-time feed of all Solasia Pharma K.K. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Solasia Pharma K.K.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Solasia Pharma K.K. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.